Grail Cancer Test
Users will first be prompted to enter their full name and email address and the Promocode.
Next, they will be prompted to pay the full $750. Once payment is made, they will receive a confirmation email that includes their unique Galleri code and a link for the next steps to order their test.
In the next steps, they will Request the Test, enter their Information (users, please be sure to mark "I have a Galleri Key" and enter the Galleri Key provided in their confirmation email) and fill out the health questionnaire.
Please use the Promo Code SMSFIELD
Grail Cancer Test
Important Safety Information
The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider.
Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.
Results should be interpreted by a healthcare provider in the context of medical history, clinical signs, and symptoms. A test result of "Cancer Signal Not Detected" does not rule out cancer. A test result of "CancerSignal Detected" requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirm cancer.
If cancer is not confirmed with further testing, it could mean that cancer is not present or that testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.
Laboratory / Test Information
GRAIL's clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA)and accredited by the College of American Pathologists (CAP). GRAIL developed the Galleri test and determined its performance characteristics. The Galleri test has not been cleared or approved by the Food and Drug Administration. GRAIL's clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.
References
1. Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167 - 1177. doi: 10.10